Table 1.

Patients’ characteristics

Characteristic	Cohort (N = 19)
Median age during IMC—yr (IQR)	63 (58–72.5)
Male sex—n. (%)	8 (42.1%)
White race—n. (%)	17 (89.5%)
Cancer type—n. (%)
Melanoma	11 (57.9%)
GU	1 (5.3%)
Lung	2 (10.5%)
Breast	1 (5.3%)
Head and neck/endocrine	3 (15.8%)
Hematological cancer	1 (5.3%)
Cancer stage IV	11 (57.8%)
Immune checkpoint inhibitor type—n. (%)
PD-1/L1	10 (52.6%)
Combination of CTLA-4 and PD-(L)1	9 (47.4%)
Median no. of ICI infusions before IMC (IQR)	6 (2–9)
Immunotherapy was stopped because of IMC—n. (%)	18 (94.7%)

CTLA-4, cytotoxic T-lymphocyte associate protein-4; GU, genitourinary; IMC, immune-mediated colitis; IQR: interquartile range; PD-(L)1, programmed cell death protein (ligand) 1.